Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AC708 |
Synonyms | |
Therapy Description |
PLX73086 (AC708) is a small molecule inhibitor of CSF1R, which leads to reduced CSF1R activation and may restore resistance to angiogenesis inhibition through a decrease in tumor associated macrophages (PMID: 29228548). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AC708 | PLX73086|PLX 73086|AC-708|AC 708 | CSF1R Inhibitor 28 | PLX73086 (AC708) is a small molecule inhibitor of CSF1R, which leads to reduced CSF1R activation and may restore resistance to angiogenesis inhibition through a decrease in tumor associated macrophages (PMID: 29228548). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02673736 | Phase I | AC708 | A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor | Terminated | USA | 0 |